Research To Practice | Oncology Videos podcast

#Science #Medicine #Cancer #Neillove #Oncology #Researchtopractice #Fitness #Dr Neil Love #Video

30:22

If your marketing grew like a dividend-reinvestment plan, would you still let a quarterly target dictate every decision? Agility requires stacking returning gains faster than the market changes—think compound interest, but for marketing campaigns. Today we’re going to talk about the Compound Marketing Engine, agentic AI, and why “data-driven” still needs greater adoption among leaders. To help me discuss this topic, I’d like to welcome Chris O'Neill, CEO of GrowthLoop. About Chris O'Neill Chris O’Neill is CEO of GrowthLoop and a board director at Gap Inc. (NYSE: GPS). His 25+ year career includes leadership roles at Google Canada, Evernote, and Xero, and board experience at Tim Hortons. As an advisor and investor, his portfolio includes Koho, Plus AI, and Neeva (acquired by Snowflake). Chris lives in Northern California with his wife, two children, and their dog Teddy. Chris O'Neill on LinkedIn: https://www.linkedin.com/in/croneill/ Resources GrowthLoop: https://www.growthloop.com https://www.growthloop.com The Agile Brand podcast is brought to you by TEKsystems. Learn more here: https://www.teksystems.com/versionnextnow Catch the future of e-commerce at eTail Boston, August 11-14, 2025. Register now: https://bit.ly/etailboston and use code PARTNER20 for 20% off for retailers and brands Don't Miss MAICON 2025, October 14-16 in Cleveland - the event bringing together the brights minds and leading voices in AI. Use Code AGILE150 for $150 off registration. Go here to register: https://bit.ly/agile150 " Connect with Greg on LinkedIn: https://www.linkedin.com/in/gregkihlstrom Don't miss a thing: get the latest episodes, sign up for our newsletter and more: https://www.theagilebrand.show Check out The Agile Brand Guide website with articles, insights, and Martechipedia, the wiki for marketing technology: https://www.agilebrandguide.com The Agile Brand is produced by Missing Link—a Latina-owned strategy-driven, creatively fueled production co-op. From ideation to creation, they craft human connections through intelligent, engaging and informative content. https://www.missinglink.company…

Research To Practice | Oncology Videos

maison des série•Feed

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

727 episodes

Research To Practice | Oncology Videos

updated il y a environ un jour

maison des série•Feed

727 episodes

#Science #Medicine #Cancer #Neillove #Oncology #Researchtopractice #Fitness #Dr Neil Love #Video

كل الحلقات

Research To Practice | Oncology Videos

1
Acute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 Mutations (Companion Faculty Lecture) 34:08

il y a 1 day34:08

34:08

Featuring a slide presentation and related discussion from Dr Jorge Cortes, including the following topics: Oncology Today with Dr Neil Love: Perspectives on New Datasets in FLT3- and IDH1/2-Mutant Acute Myeloid Leukemia — Dr Cortes (0:00) CME information and select publications

Research To Practice | Oncology Videos

1
Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances 59:03

il y a environ 5 jours59:03

59:03

Featuring perspectives from Dr Benjamin Levy, including the following topics: Introduction: The Boards (0:00) Immune Checkpoint Inhibition for Localized Non-Small Cell Lung Cancer (NSCLC) (11:43) Immunotherapy for Metastatic NSCLC (24:41) Antibody-Drug Conjugates (33:46) Novel Bispecific Antibodies (42:08) Journal Club with Dr Levy (51:28) CME information and select publications…

Research To Practice | Oncology Videos

1
Multiple Myeloma — Optimizing the Selection of First-Line Therapy 57:12

il y a environ 6 jours57:12

57:12

Featuring perspectives from Prof Xavier Leleu and Dr Peter Voorhees, including the following topics: Introduction: Myeloma Time Capsule (0:00) Smoldering Myeloma (7:21) Autologous Stem Cell Transplant (ASCT) Eligible Patients (13:05) ASCT Ineligible Patients (32:18) Subcutaneous Anti-CD38 Antibodies (47:24) Special Considerations (54:27) CME information and select publications…

Research To Practice | Oncology Videos

1
Multiple Myeloma | Peter Voorhees, MD 1:00:09

il y a environ 6 jours1:00:09

1:00:09

Optimizing the Selection of First-Line Therapy for Patients with Multiple Myeloma | Faculty Presentation — Peter Voorhees, MD CME information and select publications

Research To Practice | Oncology Videos

1
Breast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates 20:18

il y a environ 10 jours20:18

20:18

Featuring an interview with Dr Erika Hamilton, including the following topics: Optimal selection and sequencing of available antibody-drug conjugates for HR-positive metastatic breast cancer (0:00) Bardia A et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01. J Clin Oncol 2025;43(3):285-96. Abstract Pistilli B et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival from the Phase III TROPION-Breast01 trial. ESMO Virtual Plenary 2025; Abstract VP1-2025 . First-line use of sacituzumab govitecan in combination with pembrolizumab for advanced triple-negative breast cancer (8:02) Tolaney SM et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. ASCO 2025; Abstract LBA109 . Ongoing trials evaluating datopotamab deruxtecan in earlier lines of therapy (12:06) Dent RA et al. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol 2023;19(35):2349-59. Abstract McArthur HL et al. TROPION-Breast04: A randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer. Ther Adv Med Oncol 2025;17:17588359251316176. Abstract Bardia A et al. TROPION-Breast03: A randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol 2024;16:17588359241248336. Abstract Schmid P et al. TROPION-Breast05: A randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol 2025;17:17588359251327992. Abstract Available data with and ongoing trials of sacituzumab tirumotecan for HR-positive, HER2-negative and triple-negative breast cancer (16:53) Yin Y et al. Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. ASCO 2025; Abstract 1019 . Xu B et al. Sacituzumab tirumotecan in patients with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the Phase III Opti-TROP-Breast01 study. ASCO 2024; Abstract 104 . Yin Y et al. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: A randomized phase 3 trial. Nat Med 2025;31(6):1969-1975. Abstract Garrido-Castro AC et al. SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic HR+/HER2-negative breast cancer. ASCO 2024; Abstract LBA1004 . CME information and select publications…

Research To Practice | Oncology Videos

1
Gynecologic Cancers — Year in Review Series on Relevant New Datasets and Advances 59:34

il y a environ 11 jours59:34

59:34

Featuring perspectives from Prof Susana Banerjee and Dr Ursula Matulonis, including the following topics: Introduction: Tale of Two Cities — ASCO 2025 (0:00) Ovarian Cancer (11:20) HER2-Positive Gynecologic Cancers (31:28) Endometrial Cancer (40:16) Cervical Cancer (51:14) CME information and select publications…

Research To Practice | Oncology Videos

1
Endometrial and Cervical Cancer | Susana Banerjee, MBBS, MA, PhD 28:13

il y a environ 12 jours28:13

28:13

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gynecologic Cancers | Faculty Presentation 2: Endometrial Cancer and Cervical Cancer — Susana Banerjee, MBBS, MA, PhD CME information and select publications

Research To Practice | Oncology Videos

1
Ovarian Cancer | Ursula Matulonis, MD 36:24

il y a environ 12 jours36:24

36:24

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gynecologic Cancers | Faculty Presentation 1: Ovarian Cancer — Ursula Matulonis, MD CME information and select publications

Research To Practice | Oncology Videos

1
Oncology Nursing Update: Prostate Cancer — An Interview with Ms Kathleen D Burns on the Current Treatment Paradigm and New Approaches to Patient Care 44:12

il y a environ 13 jours44:12

44:12

Featuring an interview with Ms Kathleen D Burns, including the following topics: Case: A man in his early 70s with metastatic hormone-sensitive prostate cancer who received an androgen receptor inhibitor in combination with androgen deprivation therapy (0:00) Case: A man in his early 70s with metastatic castration-resistant prostate cancer (mCRPC) who received olaparib in combination with abiraterone (23:20) Case: A man in his mid 70s with mCRPC who received lutetium Lu 177 vipivotide tetraxetan (33:44) NCPD information and select publications…

Research To Practice | Oncology Videos

1
Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management 27:45

il y a environ 15 jours27:45

27:45

Featuring an interview with Dr Hope S Rugo, including the following topics: Pharmacologic features of antibody-drug conjugates (ADCs) and implications for their efficacy and toxicity in HR-positive breast cancer (0:00) Clinical and biological factors influencing the sequencing of approved ADCs for HR-positive and triple-negative metastatic breast cancer (4:03) Management of common toxicities with approved ADCs (10:48) Sacituzumab govitecan as first-line therapy for metastatic triple-negative breast cancer (18:17) Trastuzumab deruxtecan in combination with pertuzumab as first-line therapy for HER2-positive metastatic breast cancer (21:09) CME information and select publications…

Research To Practice | Oncology Videos

1
Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management (Companion Faculty Lecture) 39:01

il y a environ 15 jours39:01

39:01

Featuring a slide presentation and related discussion from Dr Hope S Rugo, including the following topics: Current treatment landscape for and outcomes in HR-positive, HER2-negative metastatic breast cancer (mBC) (0:00) Trastuzumab deruxtecan for HER2-low and HER2-ultralow mBC (7:49) Sacituzumab govitecan for HR-positive, HER2-negative mBC (20:44) Datopotamab deruxtecan for HR-positive, HER2-negative mBC (27:29) Novel antibody-drug conjugates under investigation for HR-positive mBC (33:19) CME information and select publications…

Research To Practice | Oncology Videos

1
Soft Tissue Sarcoma and Other Connective Tissue Neoplasms — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting 1:00:57

il y a environ 19 jours1:00:57

1:00:57

Featuring perspectives from Dr Rashmi Chugh and Dr Mrinal Gounder, including the following topics: Introduction: Current Role of General Medical Oncologists in the Treatment of Soft Tissue Sarcomas (STS) (0:00) Incorporation of Novel Agents and Strategies into the Management of STS — Faculty Presentation (6:38) Incorporation of Novel Agents and Strategies into the Management of STS — Survey Questions (20:34) Evolving Treatment Paradigm for Locally Aggressive STS — Faculty Presentation (31:09) Evolving Treatment Paradigm for Locally Aggressive STS — Survey Questions (46:44) CME information and select publications…

Research To Practice | Oncology Videos

1
Renal Cell Carcinoma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting 58:54

il y a environ 20 jours58:54

58:54

Featuring perspectives from Prof Laurence Albiges and Dr Tian Zhang, including the following topics: Introduction: Adjuvant Immunotherapy for Localized Renal Cell Carcinoma (RCC) (0:00) Metastatic Clear Cell RCC — Faculty Presentation (9:22) Metastatic Clear Cell RCC — Survey Questions (20:24) Non-Clear Cell RCC — Faculty Presentation (36:02) Non-Clear Cell RCC — Survey Questions (45:46) ASCO 2025 (50:12) CME information and select publications…

Research To Practice | Oncology Videos

1
Chronic Lymphocytic Leukemia — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting 1:00:43

il y a environ 22 jours1:00:43

1:00:43

Featuring perspectives from Dr Catherine C Coombs and Dr William G Wierda, including the following topics: Introduction (0:00) Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) — Dr Wierda (19:25) First-Line Therapy for CLL — Dr Coombs (44:18) Novel Agents and Strategies for R/R CLL — Dr Wierda (57:27) CME information and select publications…

Research To Practice | Oncology Videos

1
Oncology Nursing Update: Ovarian Cancer — An Interview with Ms Jennifer Filipi on the Current Treatment Paradigm and New Approaches 53:52

il y a environ 25 jours53:52